CMT's CannaBiz Invest Asia Summit on 29-30 August, 2019 in Bangkok, zooms in on the legal and commercial aspects of medical and industrial cannabis market in Asia vis-à-vis government regulations, investments, cultivation and value added products.

With more Asian countries starting to legalise medical and industrial cannabis use, major cannabis product manufacturers will convene in Bangkok for a timely summit to share insights on this new market.

Aurora Cannabis shares insights on Global Cannabis Market Outlook & Investment Landscape. Day 1 also features sessions from cannabis producers – CannAcubed presenting a case study on 'China's Industrial Hemp Cultivation & Value Chain Investment' and Elixinol Global providing the 'Growth Outlook for Hemp Foods, Protein & the CBD Market in Japan & Globally'. Coffee break sponsor – Medipharm Labs will speak on Australia's Role in APAC Medical Cannabis Market.

Other cannabis producers sharing their perspectives are:

• Blue Sky Biologicals - Hemp: Beyond CBD & THC, a Whole Plant Model
• Hikurangi Cannabis Company - Cannabis Legislation in New Zealand: Reflections on Government Efforts to Design World-Leading Medicinal Cannabis & Full Legalisation
• Bombay Hemp Company Private Limited (BOHECO) - Industrial and Medical Cannabis Investment in India – Scientific and Legal Perspective
• BOL Pharma - From Farm to Pharmaceutical Products – Israel's Experience

Thailand - the first Southeast Asian country to legalise cannabis use for medical purposes – gather 2 experts providing details on – 'Understanding the Medical Cannabis Investment Landscape & Regulatory Hurdles in Thailand' - Tilleke & Gibbins International and 'Integration of Medical Cannabis in Thai Traditional Medicine - A Balancing Game' - Dept. of Thai Traditional and Alternative Medicine, Ministry of Health.

Organised by Centre for Management Technology (CMT), the program also features sessions on:

 The Future of Sustainable Fashion & Hemp Fibres Industry - Kingdom Holdings

 "Green Green Profits" - The Cultivation of Outdoor Medical Cannabis as a Business Model for Asia - Jacana Holdings

 Commercialisation of Plant-Derived Cannabinoid Prescription Medicines to Meet Global Demand - MGC Pharmaceuticals

 Pharmaceutical Development in Man-Made Cannabinoids - Akseera Pharma

In addition, MYM Nutraceuticals, Helius Therapeutics and Cannex Capital join a panel discussion on 'Accessing Capital Markets for Cannabis Investments – Options & Challenges'.